Blood markers and fluid absorption during bladder cancer surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how fluid absorbed during bladder cancer removal surgery affects cell-free DNA (tiny pieces of cancer DNA) in your blood. Researchers want to understand if these blood markers can help predict surgery outcomes and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Suspected or confirmed bladder cancer (specifically urothelial carcinoma)
- Scheduled to have TURBT—a procedure to remove bladder tumors through the urethra
- Willing to provide multiple blood samples before, during, and after surgery
- No prior bladder removal surgery or cancer chemotherapy
- No other active cancer in the past 5 years (except minor skin cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for specific DNA changes in bladder cancer tumors using a precise test. It aims to better understand the disease and may help guide future treatment choices.
This study examines whether a simple blood test can detect cancer DNA (circulating tumor DNA, or ctDNA) in patients with a specific type of bladder cancer. Detecting this DNA in blood may help doctors predict how the cancer will behave and guide future treatment decisions.
This study collects clinical and tissue samples from people who are having surgery for bladder cancer and related urinary-tract tumors. It aims to improve understanding of cancer and may help future care by building a large research dataset.
This trial is testing whether a urine test for tumor DNA/RNA can help guide the decision for a second surgery in people with high-risk, non-muscle-invasive bladder cancer. It aims to see if the urine test can predict who needs the second surgery, potentially avoiding unnecessary procedures.
This trial studies if a urine test for tumor DNA can help decide when a second surgery is needed for early stage bladder cancer. It may reduce unnecessary procedures for some patients.
This trial tests a urine test that looks for tumor DNA to help doctors decide when you need a cystoscopy (a scope in the bladder). It is for people with high-risk or very high-risk non-muscle-invasive bladder cancer who have already had surgery to remove all visible tumors.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.